HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute myelogenous leukemia following immunosuppressive therapy for rheumatoid arthritis.

Abstract
A 51-year-old woman had acute myelogenous leukemia following log-term cyclophosphamide therapy for rheumatoid arthritis. After standard methods of management had failed, the rheumatoid arthritis showed considerable improvement in response to approximately 25 mg cyclophosphamide per day over a four-year period. At the end of this period, pancytopenia developed, and cyclophosphamide was discontinued. A bone-marrow aspirate showed nonspecific changes. However, four months later because of severe progressive pancytopenia, another bone-marrow examination was performed; it showed acute myelogenous leukemia. Therapy failed to induce a remission, and two months after diagnosis the patient died of aspergillosis. Autopsy confirmed the presence of leukemic infiltration of bone marrow, lymph nodes, liver and spleen. These findings suggest a possible leukemogenic role of cyclophosphamide in this case and suggest that caution should be exercised in treating non-fatal diseases with antitumor drugs.
AuthorsS B Kapadia, S S Kaplan
JournalAmerican journal of clinical pathology (Am J Clin Pathol) Vol. 70 Issue 2 Pg. 301-2 (Aug 1978) ISSN: 0002-9173 [Print] England
PMID279231 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Cyclophosphamide
Topics
  • Arthritis, Rheumatoid (drug therapy)
  • Cyclophosphamide (adverse effects, therapeutic use)
  • Female
  • Humans
  • Leukemia, Myeloid, Acute (chemically induced)
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: